Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study by Driver, Jane A et al.
RESEARCH
Incidenceofcardiovasculardiseaseandcancerinadvanced
age: prospective cohort study
JaneADriver,instructorofmedicine,
1LucDjousse ´,assistantprofessorofmedicine,
1GiancarloLogroscino,
associate professor of neurology,
2 J Michael Gaziano, associate professor of medicine,
1,3,4 Tobias Kurth,
assistant professor of medicine and epidemiology
1,3,5
ABSTRACT
ObjectiveToinvestigatetheinfluenceofincreasingageon
the incidence and remaining lifetime risk of
cardiovascular disease and cancer in a cohort of older
men.
Design Prospective cohort study.
Setting United States.
Participants 22048 male doctors aged 40-84 who were
free of major disease in 1982.
MainoutcomemeasuresIncidenceandremaininglifetime
risk of major cardiovascular disease (myocardial
infarction,stroke,anddeathfromcardiovasculardisease)
and cancer.
Results 3252 major cardiovascular events and 5400
incident cancers were confirmed over 23 years of follow-
up. The incidence of major cardiovascular disease
continued to increase to age 100. Beginning at age 80,
however,majorcardiovasculardiseasewasmorelikelyto
bediagnosedatdeath.Theincidenceofcancerpeakedin
thoseaged80-89andthendeclined.Cancersdetectedby
screening accounted for most of the decline, whereas
most cancers for which there was no screening continued
to increase to age 100. Unadjusted cumulative incidence
overestimated the risk of cardiovascular disease by 16%
and cancer by 8.5%. The remaining lifetime risk of cancer
at age 40 was 45.1% (95% confidence interval 43.8% to
46.3%) and at age 90 was 9.6% (7.2% to 11.9%). The
remaining lifetime risk of major cardiovascular disease at
age 40 was 34.8% (33.1% to 36.5%) and at age 90 was
16.7% (12.9% to 20.6%).
Conclusions In this prospective cohort of men, the
incidence of new cardiovascular disease continued to
increase after age 80 but was most often diagnosed at
death. The decrease in incidence of cancer late in life
seemed largely due to a decline in cancers usually
detectedbyscreening.Thesefindingssuggestthatpeople
aged 80 and older have a substantial amount of
undiagnosed disease. The remaining lifetime risk of both
diseases approached a plateau in the 10th decade. This
may be due to decreased detection of disease and
reporting of symptoms and increased resistance to
disease in those who survive to old age. Accurate
estimates of disease risk in an aging population require
adjustment for competing risks of mortality.
INTRODUCTION
Heartdisease,cancer,andstrokearetheleadingcauses
of morbidity and mortality in developed nations.
1
Their burden is predicted to grow substantially over
the next generation as the result of increased life
expectancy.
23 Age is perhaps the most powerful risk
factor for cardiovascular disease and cancer, both of
which increase exponentially between ages 40 and 80.
However,thereissomeevidencethatriskmaydecline
after age 80.
4-6 Data on incidence in the ninth and 10th
decades are sparse, particularly in men. As people of
advanced age (80 and older) are the fastest growing
segment of most populations worldwide,
7 a clearer
understanding of their true experience of illness is
critical to determining the impact of increased life
expectancy on overall burden from disease.
The measurement and interpretation of the inci-
dence of disease in advanced age is complex. Lower
incidence in late life may reflect decreased screening
and medical surveillance rather than decreased risk.
Exposures to environmental and behavioural risk
factors may also differ between younger and older
people.Inaddition,traditionalmeasuresofcumulative
incidence overestimate the true risk of disease when
competing risks of death from other causes are high.
8
To investigate further the incidence of disease in
advanced age, we estimated the age specific incidence
and remaining lifetime risk of cardiovascular disease
and cancer up to age 100 in a large prospective cohort
ofmenwith23yearsoffollow-up.Thiscohortofhealth
conscious doctors has several advantages for studying
the incidence of disease in men of advanced age, as it
has a large proportion of participants surviving to age
90andbeyond,
9aswellasahigherlevelofscreeningfor
disease and diagnosis than in a general population.
METHODS
The Physicians’ Health Study is a completed rando-
mised trial of aspirin (325 mg every other day) and β
carotene (50 mg on alternate days) for the primary
prevention of cardiovascular disease and cancer
among 22071 male doctors in the United States.
Participants provided written informed consent.
Detailed descriptions of the study design and findings
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1011 At study entry in
1982, participants were aged between 40 and 84 and
had no history of cardiovascular disease, cancer (with
the exception of non-melanoma skin cancer), or other
serious illnesses. In total, 92.2% of the participants
identifiedtheirraceaswhite.Baselineinformationwas
self reported and collected by a postal questionnaire
thataskedaboutmanylifestylevariablesandotherrisk
factors for cardiovascular disease and cancer. Partici-
pants were sent follow-up questionnaires asking about
studyoutcomesandothermedicalinformationtwicein
the first year and yearly thereafter. Follow-up after the
trial is ongoing.
12 In this analysis we used follow-up
information up to 30 March 2007.
Ascertainment of cancer and cardiovascular diseases
Non-fatal cases of cancer and cardiovascular diseases
were self reported by participants on follow-up
questionnaires,andfatalcaseswerereportedbyfamily
members or next of kin. Reports of coronary revascu-
larisation procedures (coronary bypass surgery and
percutaneous coronary angioplasty) and new onset
angina were also recorded. We obtained the medical
records for all reported cancers (excluding non-
melanoma skin cancers) and major cardiovascular
events,definedasnon-fatalmyocardialinfarction,non-
fatal stroke, or death from ischaemic heart disease or
stroke. Cases of cancer, major cardiovascular disease,
and death were confirmed by review of the partici-
pants’ medical records by the endpoints committee of
the Physicians’ Health Study, which included two
internists, a cardiologist, and a neurologist. Review of
pathologyreportswasrequiredfortheconfirmationof
reported malignancies. Non-fatal myocardial infarc-
tion was confirmed using the World Health Organiza-
tion criteria, and if the event was associated with
diagnostic electrocardiograms or increased levels of
cardiac enzymes.
13 Non-fatal stroke was defined as a
typical neurological deficit, sudden or rapid in onset
andlastingmorethan24hours,thatwasattributedtoa
cerebrovascular event. Death due to ischaemic heart
disease or stroke was confirmed by convincing
evidencebasedonavailableinformationfrommedical
recordsordeathcertificates,andfordeathsoutsidethe
hospital from family members or next of kin. For this
analysiswe usedonlyconfirmed events.Majorcardio-
vascular disease was defined as non-fatal myocardial
infarction, non-fatal stroke, or death from cardio-
vascular disease. For the end point all cardiovascular
disease, we also considered self reported angina and
revascularisation procedures. If a participant reported
more than one end point, we used the first event to
occur to define the onset of disease.
Statistical analysis
We excluded participants who reported a history of
cancer (n=19) or of major cardiovascular disease (n=4)
before receiving the baseline questionnaire, leaving
22048menforthisanalysis.Age(inyears)wasusedas
the time scale. Follow-up began at baselineage and we
censoredparticipantsattheagetheydevelopedtheend
pointofinterest, died,or reachedthe endoffollow-up.
Since few participants lived beyond the 10th decade,
we censored data for when patients reached 100 years
of age. We calculated one year crude incidence (per
100000 person years) for each age and then collapsed
theseinto10yearagegroups.Westratifiedagespecific
incidence by smoking status (ever v never). Using a
modified Kaplan-Meier method we estimated the
cumulative incidence of major cardiovascular disease
or cancer conditional on survival to age 40.
14 To
understand the influence of mortality on estimates of
disease incidence in very old people, we calculated
remaining lifetime risk using a method described
previously.
15 We calculated the remaining lifetime
risk of cancer, major cardiovascular disease, and
overall cardiovascular disease for those who reached
the ages of 50, 60, 70, 80, and 90 free of the disease of
interest.
Weproducedincidenceestimatesusingthepractical
incidence estimatorsmacro,which has been described
in detail
8 and used in several previous analyses.
561617
StatisticalcalculationsweredoneusingSASversion9.1
software.
RESULTS
Table 1 shows the baseline characteristics of the
participantsbyageatentrytothestudy.Atotalof3051
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Fig 1 | Crude incidence of overall cancer and major
cardiovascular disease by age
Table 1 |Baseline characteristics of participants in Physicians’ Health Study. Values are
percentages of participants
Variables
<55 years
(n=13 003)
55-64 years
n=5994)
≥65 years
(n=3051)
Smoking status:
Former 35.3 44.5 47.2
Current 10.9 11.9 9.4
Daily alcohol use 20.6 28.5 36.1
Exercise to sweat 1-3 times or less
monthly
26.2 29.1 31.5
Body mass index:
25-29 kg/m
2 36.9 41.3 37.8
≥30 kg/m
2 4.4 4.1 3.6
Diabetes 1.1 2.8 5.3
Hypertension 16.2 29.8 44.6
High cholesterol level 10.0 14.4 15.1
RESEARCH
page 2 of 8 BMJ | ONLINE FIRST | bmj.comparticipants were aged 65 or older at study baseline.
After 23 years of follow-up (478692 person years),
76.5% of the cohort was still alive. Overall, 32142
person years had accruedin men aged 80-89 and 3312
person years in those aged 90-99. During follow-up,
3252 cases of major cardiovascular disease and 5400
incident cancers were confirmed. The incidence of
majorcardiovasculardiseasecontinuedtorisethrough
the10thdecade,witharateof3110per100000person
years (fig 1). In contrast, the age specific incidence of
overallcancerincreasedsteadilyfrom160per100000
person years in those aged 40-49 to 2555 per 100000
person years in those aged 80-89. It then declined to
2264 per 100000 person years in those aged 90-99.
Whereas cardiovascular disease diagnosed at death
increased dramatically with age, the incidence of non-
fatalmyocardialinfarctiondeclined,andtheincidence
of non-fatal stroke increased only slightly after age 89
(fig 2). Revascularisation procedures and angina
declined noticeably with age as the first manifestation
of cardiovascular disease, whereas the rate of
confirmed major cardiovascular disease events con-
tinuedtoincreasewithage(fig3).Table 2showstheage
specific incidence of cardiovascular disease by sub-
types.
Table 3displaystheagespecificincidenceofcancer
by subtypes. The most common cancers were prostate
(47.2%), colorectal (10.3%), lymphoma (6.6%), lung
(6.6%),and melanoma(5.7%). Mostofthe cancers that
declined before age 100 were those detected by
screening, whereas the incidence of cancers for which
therewasnoroutinescreeningcontinuedtoincreaseup
to age 99 (fig 4). The cancer rate among ever smokers
peakedinthoseaged80-89,at2883per100000person
years,andthendeclined,whereastherateamongnever
smokerspeakedat2205per100000personyearsinthe
ninthdecadeandthenremainedstable.Incontrast,the
incidence of major cardiovascular disease increased
through the 10th decade in both smokers and non-
smokers (data not shown).
Adjustment for competing risks of death clearly
attenuated the estimate of cumulative incidence for
both major cardiovascular disease and cancer (fig 5).
Whereas cumulative incidence continued to increase
among the oldest participants, mortality adjusted
curvestendedtoflattenoutinthe10thdecade.Table 4
shows the remaining lifetime risk of major diseases for
menwhoreachedvariousindexagesfreeofthedisease
of interest. The risk of both cardiovascular disease and
cancer decreased as remaining lifetime diminished.
Theriskofmajorcardiovasculardiseasein40yearolds
was 34.8% (33.1% to 36.5%) and in 90 year olds was
16.7% (12.9% to 20.6%).The risk of any cancer in
40yearoldswas45.1%(95%confidenceinterval43.8%
to46.3%)andin90yearoldswas9.6%(7.2%to11.9%).
DISCUSSION
In this large prospective cohort of US male doctors
without serious diseases at entry to the study, the
incidence of major cardiovascular disease increased
exponentiallythroughthe10thdecade.Incontrast,the
incidenceofcancerpeakedinmenaged80-90andthen
declined. In those aged more than 80, new cases of
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Fig 3 | Age specific crude incidence of major cardiovascular
disease compared with angina and revascularisation
procedures as first cardiovascular disease events. Curvefor all
cardiovascular disease includes angina and revascularisation
in addition to major end points. Participants were considered
to have cardiovascular disease at first end point reported
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Fig 2 | Age specific crude incidence of confirmed major
cardiovascular disease by type of first event (non-fatal
myocardial infarction, non-fatal stroke, and death from
cardiovascular disease)
Definitions
17 29 30
Competing risks—study participants who may be removed from follow-up—for example,
becauseofdeath from causesotherthan the disease ofinterest.The effectisminimal over
short periods but significant when follow-up is long or participants are older and have an
increased risk of death from many causes
Incidence—number of participants who develop a disease divided by the sum of the time
contribution(persontime)forallparticipantsfollowed.Accountsforcompetingriskandloss
to follow-up, as participants only contribute actual time they are followed in the study.
Usuallyexpressedasanannualincidence—forexample,50casesper100000personsper
year
Cumulative incidence—commonly used to estimate the long term risk of developing a
disease. Assumes no loss to follow-up and that those who die would have developed the
disease at the same rate as survivors; however, those who die have no risk. Leads to
overestimation of risk when the population prevalence of a condition is more than 10% or
competing risks of death are high
Remaining lifetime risk—estimates the absolute risk of ever developing a disease before
dying of something else. Adjusts cumulative incidence for competing risks of death.
Provides one summary measure of absolute risk for the remainder of one’sl i f e t i m e —for
example,alifetimeriskof25%,or1in4.Appropriatemeasureforindividualandpopulation
risk
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death. The decrease in incidence of cancer late in life
seemed largely due to a decline in cancers detected by
screening. The cumulative incidence of both cardio-
vascular diseaseand cancer were clearlyattenuatedby
adjustmentforriskofmortality.Theremaininglifetime
risk of both diseases decreased with advancing age.
Incidence of cardiovascular disease
Previousstudieshavereportedanincreasingincidence
ofcardiovasculardiseasein theoldest participants,but
those aged 85 and older were combined in a single
group.
1819 The rate of major cardiovascular disease in
ourstudycontinuedtoincreaseuptoage99.However,
the rate of non-fatal myocardial infarction declined
after age 89, whereas that of non-fatal stroke reached a
plateau by age 90. The decline in non-fatal
cardiovascular events in the face of increased deaths
due to cardiovascular disease suggests that people of
advanced age may be living with a substantial amount
of undiagnosed cardiovascular disease. Self reported
revascularisation procedures and angina declined
noticeably after age 79. This may be due in part to
decreased symptoms or decreased reporting, but may
also reflect a decrease in aggressive medical care and
diagnostic procedures. When we considered events
basedonsymptoms(angina)orcoronaryproceduresas
the first manifestation of cardiovascular disease, age
specific incidence approached a plateau in the oldest
participants, illustrating the importance of defining
disease when doing incidence studies.
Cancer incidence
Manystudieshaveshownasharpincreaseinincidence
ofcancerwithage.Ourfindingsofadeclineafterage89
agree with those of other large cohorts with sufficient
follow-up.
420They are similar to results of an analysis
using the 1995-7 data from SEER (Surveillance,
Epidemiology, and End Results), a US cancer registry
programme.
21 The incidence of invasive cancer in
whitemenpeakedatasimilaragerangetoours(85-89)
and at about the same incidence (2500 per 100000),
and then declined.
However, the decrease in incidence of cancer late in
lifeseemedtobelargelydrivenbycancersdetectedby
screening. The most dramatic decline was in prostate
cancer, which accounted for 47% of all cancers
diagnosed in the Physicians’ Health Study. Prostate
cancer peaked the earliest of all cancers, in those aged
70-79. Melanoma and colorectal cancer declined after
age 89. With the exception of lymphoma and tumours
Table 2 |Age specific incidence of cardiovascular disease by subtype in participants of Physicians’ Health Study
Variables
No of
events
Incidence per 100 000 person years (95% CI)
40-49 years 50-59 years 60-69 years 70-79 years 80-89 years 90-99 years Overall
Person years of
follow-up
— 46 901 125 436 160 772 99 028 32 142 3312 467 591
Confirmed end
points:
Majorcardiovascular
disease*
3252 104.5 (77.29 to
138.12
333.2 (302.05 to
366.76)
579.7 (543.08 to
618.16)
1107.8 (1043.21to
1175.31)
2031.6 (1878.80 to
2193.63)
3110.4 (2538.72 to
3772.3)
695.5 (671.76 to
719.82)
Non-fatalmyocardial
infarction
1430 68.2 (46.64 to
96.27)
209.9 (185.28 to
236.73)
311.4 (284.81 to
339.71)
414.7 (376.16 to
456.11)
545.4 (470.24 to
629.22)
434.5 (248.38 to
705.69)
300.6 (285.26 to
316.63)
Non-fatal stroke 1210 27.7 (14.74 to
47.33)
84.5 (69.25 to
102.11)
184.6 (164.44 to
206.49)
454.8 (414.77 to
497.63)
807.1 (715.31 to
907.36)
849 (576.84 to
1205.03)
251.3 (237.39 to
265.92)
Death from
cardiovascular
disease
612 8.5 (2.31 to 21.79) 37.0 (27.18 to
49.19)
72.4 (60.34 to
86.52)
184.9 (160.08 to
212.43)
497.3 (428.24 to
574.39)
1,373.6 (1037.55
to 1783.72)
124.9 (115.18 to
135.17)
Self reported end
points:
Angina 3521 227.2 (185.99 to
274.76)
496.9 (502.58 to
589.81)
906.0 (858.95 to
954.87)
1,207.8 (1137.51
to 1281.40)
1,020.9 (907.90 to
1144.08)
513.1 (293.26 to
833.21)
788.5 (762.66 to
814.98)
CABG or PTCA 2197 81.0 (57.32 to
111.18)
277.7 (249.25 to
308.41)
536.8 (501.54 to
574.00)
773.9 (719.87 to
830.80)
552.0 (474.71 to
638.25)
242.6 (110.91 to
460.45)
470.2 (450.78 to
490.31)
All cardiovascular
disease†
4517 246.9 (203.88 to
296.41)
571.1 (529.47 to
615.10)
1038.7 (987.65 to
1091.65)
1719.7 (1633.04to
1809.86)
2338.9 2156.09 to
2533.13)
2827.1 (2219.97 to
3549.20)
1044.8 (1014.58 to
1075.75)
CABG=coronary artery bypass grafting; PTCA=percutaneous coronary angioplasty.
*Confirmed end points of myocardial infarction, stroke, or death from cardiovascular disease.
†Self reported angina or revascularisation procedures are included as cardiovascular disease defining events as well as confirmed end points of myocardial infarction, stroke, or death from
cardiovascular disease.
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continued to increase to age 100. Gastrointestinal
malignancies and tumours of unknown origin became
particularly prominent with age, as has been shown in
otherstudies.
420Ourfindingssuggestthata substantial
partofthedeclineinoverallincidenceofcancerlatein
life is accounted for by decreased ascertainment of
diseaseandmaynotrepresentatruedecreaseinrisk.It
is also possible that our participants were less likely to
report new diagnoses of cancer in advanced age.
However, the fact that cancers not detected by screen-
ing peaked later in our cohort than in other studies
possibly reflects the higher level of medical surveil-
lance and reporting of symptoms in this cohort of
doctorsthanwouldbethecaseinageneralpopulation.
Despite the overall decline in its incidence, cancer
clearly remains an important cause of disease in
advancedage.Aslifeexpectancycontinuestoincrease,
research on the benefits of individualised screening
programmes for people aged more than 80 is
warranted.
Lifetime risks
While the cumulative incidence curve shows cardio-
vascular disease increasing sharply to age 100, adjust-
ment for competing risks of death resulted in a
substantial decrease in risk in men aged 80 or more
(fig 5). A similar decrease was seen for cancer.
Cumulative incidence overestimated the actual risk of
cardiovascular disease in our population by 16% and
cancerby8.5%.Ourfindingsunderlinetheimportance
of taking mortality into account when predicting
disease risk in a cohort of elderly people.
The remaining lifetime risk of major cardiovascular
diseasedecreasedfrom1in2formenaged40to1in6for
men aged 90. When we used a broader definition of
cardiovascular disease the remaining lifetime risk at age
40washigher(41.3%v34.8%),whereastheriskatage90
was lower (16.7% v 13.7%). This is because some
participants reported angina or revascularisation proce-
dures before a major cardiovascular event, thus shifting
their date of diagnosis to earlier in life. The age specific
and cumulative incidence curves would suggest that
cardiovasculardiseaseisintimatelyrelatedtothenormal
aging of the host and that its incidence continues to
increase indefinitely with age.
22 However, lifetime risk
curvesshowthattheincidenceofcardiovasculardisease
begins to plateau later in life, as any increased risk is
outpaced by competing risks of death. This has been
shown in previous studies of coronary heart disease and
stroke.
56In contrast, the remaining lifetime risk of heart
failure, a true age dependent disease, is the same in
80 year olds as in40 year olds.
16Cancer is often thought
of as inextricably linked with aging, but it seems to fit
better the pattern of age related diseases that occur in a
particular age range and then decline. The remaining
Table 3 |Age specific incidence of overall and specific cancers in participants of Physicians’ Health Study
Variables
No (%) of
cancers
Incidence per 100 000 person years (95% CI)
40-49 years 50-59 years 60-69 years 70-79 years 80-89 years 90-99 years Overall
Person years of follow-up — 46 838 125 132 157 849 92 701 29 076 2960 454 557
Cancer subtype:
All cancers 5400 (100.0) 160.1 (125.95 to
200.72)
431.5 (395.90 to
469.51)
1242.3 (1187.96
to 1298.53)
2172.6 (2078.73
to 2269.59)
2555.3 (2374.86
to 2745.82)
2263.5 (1754.20
to 2874.57)
1188.0 (1156.53
to 1220.05)
Prostate 2548 (47.2) 4.3 (0.52 to
15.44)
133.7 (114.15 to
155.53)
641.2 (602.21 to
681.97)
1152.6 (1084.33
to 1224.04)
1008.7 (896.08
to 1131.47)
545.2 (311.64 to
885.45)
562.3 (540.70 to
584.57)
Colorectal 554 (10.3) 15.0 (6.01 to
30.81)
52.9 (40.87 to
67.23)
114.0 (97.95 to
132.03)
209.2 (180.64 to
240.95)
351.2 (286.08 to
426.78)
307.1 (140.41 to
582.90)
122.5 (112.54 to
133.18)
Lymphoma 354 (6.6) 17.1 (7.38 to
33.68)
35.2 (25.60 to
47.30)
75.2 (62.24 to
90.05)
126.4 (104.47 to
151.64)
226.2 (174.57 to
288.28)
102.5 (21.13 to
299.43)
78.3 (70.37 to
86.91)
Lung 340 (6.3) 2.1 (0.05 to
11.90)
20.0 (12.96 to
29.55)
72.0 (59.35 to
86.58)
154.7 (130.34 to
182.39)
181.0 (135.17 to
237.35)
239.0 (96.06 to
492.23)
75.2 (67.43 to
83.65)
Melanoma 305 (5.7) 49.1 (31.15 to
73.72)
38.4 (28.34 to
50.95)
66.9 (54.73 to
81.00)
95.9 (76.94 to
118.19)
135.8 (96.55 to
185.60)
68.3 (8.27 to
246.83)
67.5 (60.12 to
75.49)
Urinary tract* 300 (5.6 ) 15.0 (6.01 to
30.81)
23.2 (15.55 to
33.35)
68.18 (55.88 to
82.40)
123.16 (101.50
to 148.07)
142.73 (102.43
to 193.63)
102.46 (21.13 to
299.43)
66.37 (59.07 to
74.32)
Other gastrointestinal† 286 (5.3) 8.6 (2.33 to
21.88)
23.2 (15.55 to
33.35)
49.1 (38.73 to
61.33)
119.9 (98.54 to
114.51)
205.3 (156.30 to
264.86)
238.9 (96.06 to
492.23)
63.3 (56.15 to
71.05)
Leukaemia 181 (3.4) 2.1 (0.05 to
11.91)
23.2 (15.55 to
33.35)
42.1 (32.53 to
53.52)
56.7 (42.34 to
74.35)
101.0 (67.63 to
145.02)
136.6 (37.22 to
349.71)
40.1 (34.43 to
46.33)
Head and neck 116 (2.2) 8.6 (2.33 to
21.88)
13.6 (7.83 to
21.80)
31.2 (23.11 to
41.29)
33.8 (22.97 to
47.98)
45.3 (24.11 to
77.43)
68.3 (8.27 to
246.79)
25.7 (21.21 to
30.79)
Unknown 101 (1.9) 2.1 (0.05 to
11.91)
8.8 (4.40 to
15.76)
18.5 (12.38 to
26.55)
36.0 (24.76 to
50.53)
73.1 (45.27 to
111.79)
204.8 (75.16 to
445.80)
22.4 (18.20 to
27.16)
Brain 97 (1.8) 2.1 (0.05 to
11.91)
18.4 (11.68 to
27.34)
23.6 (16.61 to
32.51)
22.9 (14.18 to
35.00)
45.3 (24.11 to
77.43)
68.3 (8.27 to
246.79)
21.5 (17.41 to
26.19)
Other 218 (4.0) 34.2 (19.54 to
55.51)
41.6 (31.10 to
54.60)
45.9 (35.90 to
57.79)
57.8 (43.28 to
75.58)
66.2 (39.84 to
103.33)
204.8 (75.16 to
445.80)
48.23 (42.04 to
55.08)
*Includes urinary tract and genital tumours.
†Includes oesophagus, stomach, pancreas, and hepatobiliary cancers.
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A plateau or decline in lifetime risk with age has
previously been reported for overall cancer,
21 stroke,
6
coronary artery disease,
5 and Alzheimer’s disease.
23
This may be a function of decreased life expectancy in
people of advanced age; it may also be due to the
selective survival of those who are more resistant to
disease. Those who survive disease-free to older ages
may have fewer exposures to risk factors or may be
“immune” to them. The relation between risk factors
and disease may also change. For example, although a
highcholesterollevelisawellestablishedriskfactorfor
cardiovascular disease and mortality in middle aged
people the relation is less clear in elderly people,
2425
and high levels in people aged 85 and older have been
associated with longevity.
26 Finally, the observed
decline in lifetime risk may not represent a true
decrease in risk at all but rather decreased reporting
of or diagnosis of disease.
Itisimportanttoemphasisethatestimatesoflifetime
risk strongly depend on life expectancy and they
cannotbecomparedacrosspopulationsunlessmortal-
ity rates are similar. At age 65 our participants had an
additional 25 years of life expectancy, exceeding the
national average for white men by seven years.
27 The
goal of our analysis was not to provide estimates that
would be readily applicable to men in general, but to
investigate the risk of disease in a population of very
elderly people. On the one hand a population with a
shorter life expectancy might have smaller lifetime
risks than our cohort. On the other hand a less health
consciouspopulationmighthaveahigherincidenceof
disease.
Strengths and limitations
Our study has several strengths, including the large
number of participants and outcome events, prospec-
tive design, and well defined population with a long
follow-up.End points were ascertainedand confirmed
after review of medical records. We adjusted cumula-
tive incidence for competing risks of mortality.
Several limitations must be considered. Firstly, our
findings may not be generalisable to a broader
population as our cohort consisted almost exclusively
of highly educated white men. Our participants might
have a lower risk of cancer and cardiovascular disease
than a general population for several reasons. They
were healthy at baseline and had a lower incidence of
smoking and obesity than expected. All members of
our cohort had participated in a primary prevention
trialofaspirinandβcarotene.Althoughβcarotenewas
foundtohavenoinfluenceontheriskofcardiovascular
disease or cancer,
11 randomisation to aspirin was
associated with a decreased risk of myocardial infarc-
tion but not of stroke or death from cardiovascular
disease.
10 Most participants became regular users of
aspirin after completion of the trial.
28 Aspirin use was
notassociatedwithriskofcancer.Studytreatmentthus
hadnoeffectonthestudyoutcomes,withtheexception
of lower rates of myocardial infarction. Although the
factors mentioned might influence the risk of disease,
they would not be expected to affect the shape of the
incidence curves. Our participants may also have had
increasedratesofscreening,asreflectedinhigherrates
of cancers detected by screening than in the general
population. Nevertheless, the lifetime risk for overall
cancer(45.1%)inourstudywasnearlyidenticaltothat
ofthe SEERestimate forwhitemenbased ona sample
of the US population (44.9%).
21 The lifetime risk of
stroke in men aged 55 in our cohort (15.4%) was also
similar to that of men in the population based
Framingham Heart Study (16.9%).
56 We did not
address secular trends in screening and risk factors
for disease, which might also explain changes in
incidence. Because we chose to focus our analysis
only on diseases that were confirmed outcomes of the
I
n
c
i
d
e
n
c
e
 
o
r
 
r
i
s
k
 
o
f
 
c
a
n
c
e
r
 
(
%
)
0
20
30
40
50
60
10
Crude incidence
Remaining lifetime risk
Age (years)
I
n
c
i
d
e
n
c
e
 
o
r
 
r
i
s
k
 
o
f
 
c
a
r
d
i
o
v
a
s
c
u
l
a
r
 
d
i
s
e
a
s
e
 
(
%
)
40 50 60 70 80 100 90
0
20
30
40
50
60
10
Fig 5 | Effect of adjustment for competing risks of mortality on
cumulative risk of cancer and of major cardiovascular disease.
Estimates of cumulative incidence and mortality adjusted
lifetime risk are conditional on disease free survival to age 40
Table 4 |Remaining lifetime risk of first cancer or major cardiovascular disease event by age
reached free of events in participants of Physicians’ Health Study
Age (years)
Remaining lifetime risk (%) (95% CI)
All cancer
Major cardiovascular
disease All cardiovascular disease
40 45.1 (43.8 to 46.3) 34.8 (33.1 to 36.5) 41.3 (39.9 to 42.7)
50 44.5 (43.3 to 45.7) 34.5 (32.8 to 36.2) 40.5 (39.1 to 41.9)
60 42.9 (41.6 to 44.2) 33.0 (31.2 to 34.8) 38.0 (36.5 to 39.5)
70 36.6 (35.2 to 38.0) 30.5 (28.5 to 32.4) 33.2 (31.5 to 34.9)
80 24.3 (22.5 to 26.1) 25.7 (23.3 to 29.1) 24.9 (22.7 to 27.1)
90 9.6 (7.2 to 11.9) 16.7 (12.9 to 20.6) 13.7 (10.3 to 17.2)
Remaining lifetime risk=mortality adjusted cumulative risk conditional on disease-free survival to age specified.
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important conditions such as neurodegenerative and
psychiatricdisease.Finally,despitethehomogeneityof
our population for race and education, biological
associations are expected to be similar in our study
compared with other male populations.
Conclusion
In summary, the lifetime risks of both cardiovascular
disease and cancer approached a plateau in the 10th
decade. This may be due to several factors, including
decreased detection or reporting of disease and
increased resistance to disease, and has important
implications for predicting the risk of disease in
individuals and populations. Accurate estimates of
long term risk for disease require adjustment for
competing risks of mortality, particularly in an aging
population. Finally, our results suggest that people of
advanced age may have a substantial amount of
undiagnosed disease, which may in turn contribute to
geriatricsyndromessuchasfrailty.Additionalresearch
is needed to determine if continued screening and
detection of these conditions up to and beyond age 80
might help improve health and wellbeing late in life.
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